Taysha Gene Therapies Inc (TSHA NASDAQ) stock market data APIs
$4.5298
-0.08(-1.8%)
as of March 23, 2026
Try our APIs with
free plan!
Taysha Gene Therapies Inc Financial Data Overview
Price chart is built with
Anychart
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Prev. Close
4.5298
Open
4.4535
High
4.5501
Low
4.338
52 wk Range
1.05-6.02
Market Cap
1 205 M
Shares Outstanding
274 M
Revenue
9 773 K
EPS
-0.0732
Beta
1.082
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Taysha Gene Therapies Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Taysha Gene Therapies Inc data using free add-ons & libraries
Get Taysha Gene Therapies Inc Fundamental Data
Taysha Gene Therapies Inc Fundamental data includes:
- Net Revenue: 9 773 K
- EBITDA: -109 353 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: -0.0956
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Taysha Gene Therapies Inc News
New
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities an...
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
Key Points B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end position value increased by $6.26 million due to the new holding. The new stake accounted fo...
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances
Earnings Call Insights: Taysha Gene Therapies (TSHA) Q4 2025 MANAGEMENT VIEW * CEO Sean Nolan highlighted 2025 as "a year of significant execution" for Taysha, calling attention to "compelling REV...
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha Gene Therapies logo Key Points Regulatory and trial progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal trial and obtained clearance for ...
Get Taysha Gene Therapies Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
